The takeaway
Spruce Biosciences, Inc. Common Stock shows a pronounced seasonal pattern over 6 years of data — strongest in July (+9.4%) and softest in March (−26.8%).
Right now
In July, the stock has risen 60% of years, averaging +9.4%, about +7.2 pts better than the S&P 500.
The full picture
Spruce Biosciences, Inc. Common Stock's most dependable month has been July, higher in 3 of 5 years; March has been its least reliable, up just 0% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | — | |||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | — | — | — | — | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in January (+23.4 pts); it has trailed the market most in March (−27.8 pts).
“vs S&P” is Spruce Biosciences, Inc. Common Stock’s average for a month minus the S&P 500’s average for that same month — isolating Spruce Biosciences, Inc. Common Stock’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, July has closed higher 60% of the time versus 60% across the last 6 years — the pattern is holding.
Figures are the typical (median) July return and how often it rose — the last 5 years versus the last 6(the heatmap’s default window). This verdict stays anchored to that 6-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
July looks the standout, up in 3 of 5 Julys — yet the appeal is lumpy, leaning on the occasional blow-out year rather than dependable strength.
The headline flatters a touch — its +9.4% average sits well above the +4.2% a typical year delivers, the work of a few big Julys. That reliability comes with real swings, mind — even July ranges by 24.4% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: July has cleared the S&P 500 by +7.2 points above the index. Some of that is a strong month market-wide, mind — July rises for about 61% of stocks — so the tendency is real if not unique.
A few other months pull their weight: February and September have also closed higher more often than not. At the other end of the calendar, March has been the soft spot — the weakest of 7 months that average a loss (−26.8%), and the edge isn't year-round — the stock has trailed the S&P 500 in March, April, and October. Its roughest month on record was a −85.1% March in 2024 — a reminder of how hard even a seasonal name can fall.
Hold it loosely, then: the July tendency is genuine but lumpy, more about the occasional outsized year than a gain to bank on. With a short 6-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (July), its worst (March), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2020 its best month (July, +9.4%) has run well ahead of its worst (March, −26.8%) — the heatmap above shows how steady that gap has been year to year.
July has been the strongest, averaging +9.4% and closing higher in 3 of 5 years since 2020.
It's the weakest, averaging −26.8% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade